The use of a novel MUC1 antibody to identify cancer stem cells and circulating MUC1 in mice and patients with pancreatic cancer

Journal of Surgical Oncology

Volumn 107, Issue 7, 2013, Pages 713-722

  Curry, Jennifer M ^a   Thompson, Kyle J ^b   Rao, Shanti G ^a   Besmer, Dahlia M ^a   Murphy, Andrea M ^a   Grdzelishvili, Valery Z ^a   Ahrens, William A ^b   McKillop, Iain H ^b   Sindram, David ^b   Iannitti, David A ^b   Martinie, John B ^b   Mukherjee, Pinku ^a  

^a UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE   (United States)

^b CAROLINAS MEDICAL CENTER   (United States)

Author keywords

cancer stem cells; MUC1; pancreatic cancer; TAB 004

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY TAB 004; MUCIN 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER PATIENT; CANCER STEM CELL; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; BLOTTING, WESTERN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; GLYCOSYLATION; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; MICE, NUDE; MICE, TRANSGENIC; MIDDLE AGED; MUCIN-1; NEOPLASM STAGING; NEOPLASTIC STEM CELLS; PANCREATIC NEOPLASMS; PEPTIDES; SENSITIVITY AND SPECIFICITY; UP-REGULATION;

EID: 84878314550     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23316     Document Type: Article

References (33)

1. Jemal A, Bray F, Center MM, et al.: Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Hermann PC, Huber SL, Herrler T, et al.: Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007; 1: 313-323.
3. Li C, Heidt DG, Dalerba P, et al.: Identification of pancreatic cancer stem cells. Cancer Res 2007; 67: 1030-1037.
4. Rasheed ZA, Yang J, Wang Q, et al.: Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J Natl Cancer Inst 2010; 102: 340-351.
5. Levi E, Klimstra DS, Andea A, et al.: MUC1 and MUC2 in pancreatic neoplasia. J Clin Pathol 2004; 57: 456-462.
6. Tinder TL, Subramani DB, Basu GD, et al.: MUC1 enhances tumor progression and contributes toward immunosuppression in a mouse model of spontaneous pancreatic adenocarcinoma. J Immunol 2008; 181: 3116-3125.
7. Osako M, Yonezawa S, Siddiki B, et al.: Immunohistochemical study of mucin carbohydrates and core proteins in human pancreatic tumors. Cancer 1993; 71: 2191-2199.
8. Qu CF, Li Y, Song YJ, et al.: MUC1 expression in primary and metastatic pancreatic cancer cells for in vitro treatment by (213)Bi-C595 radioimmunoconjugate. Br J Cancer 2004; 91: 2086-2093.
9. Gronborg M, Bunkenborg J, Kristiansen TZ, et al.: Comprehensive proteomic analysis of human pancreatic juice. J Proteome Res 2004; 3: 1042-1055.
10. Hollingsworth MA, Strawhecker JM, Caffrey TC, et al. Expression of MUC1, MUC2, MUC3 and MUC4 mucin mRNAs in human pancreatic and intestinal tumor cell lines. Int J Cancer 1994; 57: 198-203.
11. Berberat P, Friess H, Kashiwagi M, et al.: Diagnosis and staging of pancreatic cancer by positron emission tomography. World J Surg 1999; 23: 882-887.
12. Jiang JT, Wu CP, Deng HF, et al.: Serum level of TSGF, CA242 and CA19-9 in pancreatic cancer. World J Gastroenterol 2004; 10: 1675-1677.
13. Zalatnai A,: Pancreatic cancer-A continuing challenge in oncology. Pathol Oncol Res 2003; 9: 252-263.
14. Shore S, Raraty MG, Ghaneh P, et al. Review article: Chemotherapy for pancreatic cancer. Aliment Pharmacol Ther 2003; 18: 1049-1069.
15. Ichihara T, Nomoto S, Takeda S, et al.: Clinical usefulness of the immunostaining of the tumor markers in pancreatic cancer. Hepatogastroenterology 2001; 48: 939-943.
16. Frebourg T, Bercoff E, Manchon N, et al.: The evaluation of CA19-9 antigen level in the early detection of pancreatic cancer. A prospective study of 866 patients. Cancer 1988; 62: 2287-2290.
17. Ziske C, Schlie C, Gorschluter M, et al.: Prognostic value of CA19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine. Br J Cancer 2003; 89: 1413-1417.
18. Gendler SJ,: MUC1, the renaissance molecule. J Mammary Gland Biol Neoplasia 2001; 6: 339-353.
19. Hollingsworth MA, Swanson BJ,: Mucins in cancer: Protection and control of the cell surface. Nat Rev Cancer 2004; 4: 45-60.
20. Sahraei M, Roy LD, Curry JM, et al.: MUC1 regulates PDGFA expression during pancreatic cancer progression. Oncogene 2012; 31: 4935-4945.
21. Besmer DM, Curry JM, Roy LD, et al.: Pancreatic ductal adenocarcinoma (PDA) mice lacking Mucin 1 have a profound defect in tumor growth and metastasis. Cancer Res 2011; 71: 4432-4442.
22. Hingorani SR, Petricoin EF, Maitra A, et al.: Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 2003; 4: 437-450.
23. Rowse GJ, Tempero RM, VanLith ML, et al.: Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model. Cancer Res 1998; 58: 315-321.
24. Al-Hajj M, Wicha MS, Benito-Hernandez A, et al.: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100: 3983-3988.
25. Visvader JE, Lindeman GJ,: Cancer stem cells in solid tumours: Accumulating evidence and unresolved questions. Nat Rev Cancer 2008; 8: 755-768.
26. Hikita ST, Kosik KS, Clegg DO, et al. MUC1* mediates the growth of human pluripotent stem cells. PLoS ONE 2008; 3: e3312.
27. Engelmann K, Shen H, Finn OJ,: MCF7 side population cells with characteristics of cancer stem/progenitor cells express the tumor antigen MUC1. Cancer Res 2008; 68: 2419-2426.
28. Roy LD, Sahraei M, Subramani DB, et al.: MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transition. Oncogene 2011; 30: 1449-1459.
29. Deguchi T, Tanemura M, Miyoshi E, et al.: Increased immunogenicity of tumor-associated antigen, mucin 1, engineered to express alpha-gal epitopes: A novel approach to immunotherapy in pancreatic cancer. Cancer Res 2010; 70: 5259-5269.
30. Ugorski M, Laskowska A,: Sialyl Lewis(a): A tumor-associated carbohydrate antigen involved in adhesion and metastatic potential of cancer cells. Acta Biochim Pol 2002; 49: 303-311.
31. Magnani JL, Steplewski Z, Koprowski H, et al. Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin. Cancer Res 1983; 43: 5489-5492.
32. Banfi G, Zerbi A, Pastori S, et al.: Behavior of tumor markers CA19.9, CA195, CAM43, CA242, and TPS in the diagnosis and follow-up of pancreatic cancer. Clin Chem 1993; 39: 420-423.
33. Perkins GL, Slater ED, Sanders GK, et al. Serum tumor markers. Am Fam Physician 2003; 68: 1075-1082.